Capricor Therapeutics (CAPR) Earns News Sentiment Score of 0.19

Press coverage about Capricor Therapeutics (NASDAQ:CAPR) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Capricor Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 48.4608236316349 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

CAPR has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Tuesday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $8.60 price objective (up from $6.50) on shares of Capricor Therapeutics in a research note on Friday, January 26th.

Capricor Therapeutics (CAPR) traded down $0.11 during mid-day trading on Tuesday, reaching $1.67. The company had a trading volume of 241,831 shares, compared to its average volume of 517,619. Capricor Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $4.25. The firm has a market capitalization of $47.55, a P/E ratio of -55.65 and a beta of -3.53.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.63 million. equities analysts predict that Capricor Therapeutics will post -0.54 EPS for the current fiscal year.

WARNING: This news story was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Insider Buying and Selling by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply